1. Belgium Stocks

  2. •

    Basic Materials

  3. •

    Agricultural Inputs
Biotalys N.V.

Biotalys N.V.

BTLS.BR
Biotalys N.V.BE flagEuronext Brussels
3.04
EUR
-0.01
- -
114.18MMarket Cap
Biotalys N.V.
BTLS.BR
(Euronext Brussels)

Recent

price

3.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.26
-0.36
-1.1
-0.74
-0.65
-0.4
-0.42
Basic EPS, GAAP
- -
-0.3
-0.45
-1.17
-0.67
-0.59
-0.38
-0.37
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.81
0.96
1.69
0.81
0.19
-0.19
-0.6
Book Value per Share
- -
0.68
0.83
3.78
1.21
0.79
0.81
0.31
Tangible Book Value per Share
- -
30
30
15
31
32
33
37
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
1
1
1
2
2
2
2
Depreciation Expense
- -
-8
-11
-17
-23
-21
-13
-16
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
18
19
54
32
19
21
7
Working Capital
1
1
4
6
5
5
4
3
LT Debt
2
21
26
59
38
26
28
12
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-58.38
-40.44
-61.76
-89.14
-132.82
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2.66%
-56.16%
Free Cash Flow
- -
3.21%
8.37%
Net Income, GAAP
- -
13.15%
19.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.65
2024
- -
- -
- -
- -
-0.4
2025
- -
- -
- -
- -
-0.42

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Astec LifeSciences Limited (ASTEC.BO)
Hanfeng Evergreen Inc. (HFGVF)
Kyung Nong Corporation (002100.KS)
Dhanuka Agritech Limited (DHANUKA.BO)
Yunnan Yuntianhua Co., Ltd. (600096.SS)
Amoéba S.A. (ALMIB.PA)
Business
Biotalys N.V. (Euronext Brussels: BTLS.BR) develops protein-based biocontrol solutions for sustainable crop protection as an agricultural technology company targeting pests and diseases across the food value chain from soil to plate. The company offers a pipeline of products based on its proprietary AGROBODY™ technology platform, including the lead biofungicide EVOCA™ against botrytis and powdery mildew in fruits and vegetables, which received U.S. EPA regulatory approval in 2025 and awaits EU approval; EVOCA NG, an enhanced next-generation formulation with planned U.S. registration in 2028-29; BioFun-6 targeting additional fungal pathogens; and BioFun-8, a new biofungicide program launched in October 2024 against Alternaria leaf spot in fruits, vegetables, and potatoes, addressing a USD 1.1 billion market opportunity; as well as earlier-stage bioinsecticides and biobactericides. Biotalys serves pre- and post-harvest markets for growers seeking alternatives to chemical pesticides with novel modes of action, low environmental impact, and favorable safety profiles. Founded in 2013 as a spin-off from VIB (Flanders Institute for Biotechnology), the company maintains headquarters in Ghent, Belgium, with a North American subsidiary office in North Carolina, USA, and recently opened expanded R&D facilities there comprising 1,800 square meters of laboratory space. Recent developments include a EUR 15 million private placement in October 2024 with new investor ASR Vermogensbeheer and existing backers Ackermans & van Haaren and AIF to fund regulatory processes for EVOCA™ and EVOCA NG, field trials for BioFun-6, and pipeline expansion; addition of BioFun-8 to the R&D pipeline in 2024; a strategic partnership announced in May 2025 with AgroFresh Solutions, Inc. for post-harvest biological solutions; and ongoing academic collaborations for programs like BioFun-4.